New vaccine targets rare liver cancer's genetic flaw
NCT ID NCT06789198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cells to recognize and attack cancer cells carrying this fusion. The study will enroll about 20 participants who have achieved complete remission after standard treatments, to see if the vaccine is safe and triggers a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Tuebingen
RECRUITINGTübingen, 72076, Germany
-
Universitätsklinikum Tübingen, Kinderheilkunde I
NOT_YET_RECRUITINGTübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.